65,437 trials
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virological Response (SVR) — 79.1 percentage of participants
Heart Failure · Diastolic Heart Failure
Primary: Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose — 1.16; 1.49; 1.20; 1.44 L/min
Blood Pressure
Primary: Changes of Serum Cortisol Levels — 0.012835; 0.016206 relative intensity — p=<0.05
Adult Influenza Vaccinations · Adult PPSV Vaccinations · Adult Tdap/Td Vaccinations
Primary: Year 1 RCCT: Change From Baseline in the Percentage of Participants Who Were Vaccinated at the End of Year 1 — 7.7; 6.4; 6.5; 6.6 percent change in vaccination rates…
Lymphoma
Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants
Pain
Primary: Overall Rate of Feeling Unreality — 22; 13 Participants
Obesity · Overweight
Primary: Moderate to Vigorous Physical Activity (MVPA) — -1.9; 1.07 minutes
High Risk Acute Myeloid Leukemia
Primary: Overall Survival — 9.56; 5.95 months
Arrhythmia
Primary: Number of Patients With Arrhythmia Recurrence — 100 Participants
Tobacco Smoking Cessation · Motivation
Primary: Average Number of Completed Sessions Per Participant — 1.633; 3.052 Average Number of Sessions — p=<0.0001
Acute Lymphoblastic Leukemia · Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Sleep Apnea, Obstructive
Primary: Daytime Sleepiness — 9.0; 3.8; 6.8; 6.5 units on a scale
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.64; -0.06 Percentage change — p=<0.001
Cannabis Dependence
Primary: Tolerability — 0; 0; 0 Participants
Depression
Primary: Depression With PHQ-9 — 7.7 units on a scale